Table 3. Clinicopathological features by GOT1 status in the validation cohort.
| Characteristic | Validation Cohort N = 140 | GOT1+ N = 73 | GOT1– N = 67 | P high vs. low |
|---|---|---|---|---|
| Sex, n (%) | ||||
| male | 70 (50%) | 32 (44%) | 38 (57%) | 0.18 |
| female | 70 (50%) | 41 (56%) | 29 (43%) | |
| Age | ||||
| Median | 71 | 71 | 70 | 0.70 |
| Range | 21–89 | 21–89 | 33–85 | |
| Age ≥ 65 n (%) | 96 (69%) | 50 (68%) | 46 (69%) | 1.0 |
| Site, n (%) | ||||
| Head | 80 (58%) | 42 (58%) | 38 (57%) | 0.89 |
| Body | 37 (26%) | 20 (27%) | 17 (25%) | |
| Tail | 23 (16%) | 11 (15%) | 12 (18%) | |
| Tumor Size, n (%) | ||||
| T1/2 | 10 (12%) | 7 (14%) | 3 (10%) | 0.73 |
| T3/4 | 70 (88%) | 42 (86%) | 28 (90%) | |
| Nodal Metastasis, n (%) | ||||
| N0 | 22 (28%) | 15 (31%) | 7 (23%) | 0.45 |
| N1 | 57 (72%) | 33 (69%) | 24 (77%) | |
| Systemic Metastasis, n (%) | ||||
| M0 | 51 (39%) | 33 (49%) | 18 (29%) | 0.03 |
| M1 | 79 (61%) | 35 (51%) | 44 (71%) | |
| Stage Grouping*, n (%) | ||||
| I/II | 46* (36%) | 29 (44%) | 17 (27%) | 0.07 |
| III/IV | 82* (64%) | 37 (56%) | 45 (73%) | |
| Stage Grouping*, n (%) | ||||
| I/II/III | 47 (37%) | 29 (44%) | 18 (29%) | 0.09 |
| IV | 81 (63%) | 37 (56%) | 44 (71%) | |
| Histological Grade, n (%) | ||||
| G1/2 | 84 (60%) | 49 (67%) | 35 (52%) | 0.09 |
| G3/4 | 56 (40%) | 24 (33%) | 32 (48%) |
Abbreviations: GOT1, Aspartate Aminotransferase 1; Stage grouping according to AJCC. Note: we tallied both stage groupings to illustrate that there was only one stage III patient (GOT1–) in the combined advanced or systemic group (i.e., stage III/IV) group.